Skip to main content
Premium Trial:

Request an Annual Quote

Quintiles, London Genetics Ink PGx Services Pact

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Quintiles and London Genetics have struck a partnership to provide biomarker and pharmacogenomics consulting and services to biopharmaceutical firms, Research Triangle Park, NC-based Quintiles said today.

The two companies will collaborate to provide pharmacogenetic solutions, including novel biomarker and assay development services.

"Ultimately, our alliance will support biopharma in their interactions with academic partners and the development of personalized medicines," London Genetics CEO Dominique Kleyn said in a statement.

Among the services provided by Quintiles are biomarker tests that analyze genes and proteins that affect cell growth and mutation.

London Genetics helps companies to apply genetic knowledge that can take risk out of clinical trials. It also designs and manages projects and patient cohorts through partnerships with relevant academics and clinicians.

Thomas Wollman, senior VP of Quintiles Global Central Laboratories, said that the two firms have "expertise to help early adopters of personalized medicine use genomic technologies to improve drug discovery and development, and a networked infrastructure to support those efforts virtually anywhere in the world."

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more